NCT02581579View on ClinicalTrials.gov

Study to Evaluate the Tolerability and Immunogenicity of Nyaditum Resae ® Probiotic Administered to Pediatric Population in Contact With Tuberculosis With or Without Latent Tuberculosis Infection

NACompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 9, 2015

Primary Completion Date

March 6, 2019

Study Completion Date

March 6, 2019

Conditions

Tuberculosis

Interventions

DIETARY_SUPPLEMENT

Nyaditum resae ® 10e5 of heat-killed Mycobacterium manresensis

Nyaditum resae ® 10e5 of heat-killed Mycobacterium manresensis, 1 capsule per day during 14

OTHER

Placebo

Placebo, 1 capsule per day during 14

Trial Locations (3)

08916

Germans Trias I Pujol Hospital, Badalona

08950

Hospital Sant Joan de Déu, Esplugues de Llobregat

08035

Valle Hebron Hospital, Barcelona

All Listed Sponsors

lead

Manresana de Micobacteriologia, SL

INDUSTRY

NCT02581579 - Study to Evaluate the Tolerability and Immunogenicity of Nyaditum Resae ® Probiotic Administered to Pediatric Population in Contact With Tuberculosis With or Without Latent Tuberculosis Infection | Biotech Hunter | Biotech Hunter